ViGenCell Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ViGenCell Inc. - overview
Established
2013
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Based in Seoul, South Korea, ViGenCell Inc. is a biotechnology company specializing in immune cell therapy. The firm was founded as the first subsidiary of Catholic University Technology Holdings Co. , Ltd.
in 2013. In December 2024, GAEUN GLOBAL Co. ,Ltd acquired an 11. 37% minority stake in ViGenCell from Boryung Biopharma Co.
, Ltd. The firm as of December 2024, is led by its CEO, Kim Tae-gyu. The company focuses on the development of advanced immunotherapies utilizing T cells, myeloid-derived suppressor cells (MDSC), and gamma-delta T cells, aimed at improving patient outcomes and extending lives with intractable diseases. Bizencell’s core technologies include its ViTier™ antigen-specific killer T cell therapy, ViMedier™ cord blood-derived myeloid suppressor cell therapy, and ViRanger™ universal T cell gene therapy.
These therapies are designed to target specific cancer cells or modulate immune responses in conditions like leukemia, lymphoma, atopic dermatitis, and graft-versus-host disease.
Current Investors
Woori Bank, Shinhan Venture Investment, Brain Asset Management
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.vigencell.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
ViGenCell Inc. - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 32,745,630 | 15,031,590 | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | (54.1%) | - | - | - | - | - | - |
| EBITDA (USD) | (1,225,284,548) | (4,757,719,919) | 8,674,443,338 | - | - | - | - | - |
| Operating Income (USD) | (1,290,046,094) | (4,954,778,037) | 7,912,700,310 | - | - | - | - | - |
| Operating Margin | (3939.6%) | (32962.4%) | - | - | - | - | - | - |
| % EBITDA Margin | (3741.8%) | (31651.5%) | - | - | - | - | - | - |
| NET Income (USD) | (6,507,116,668) | (22,452,705,694) | (10,454,734,387) | - | - | - | - | - |
| % Net Margin | (19871.7%) | (149370.1%) | - | - | - | - | - | - |
ViGenCell Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | ViGenCell Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.